https://s m...

https://s m allcaps.com.au/australian-biotech-sector-tipped-strong-growth/
(close the gaps to make link work)
IMU gets a mention in this article on Australian biotechs. (story from 19 Mar 24). The article also mentions a KPMG study in the sector with a forecast Australia could generate $15B in exports the the US. Relevance? As awareness of IMU grows so too will FOMO (IMHO). I would expect that number to be small if any of the biotechs mentioned hit the jackpot.

ImugeneImugene’s (ASX: IMU) Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics has cleared its first cohort within the intratumoural monotherapy arm of the study.Imugene is now ready to commence combination dosing solid tumour patients with CD19-targeting drug blinatumomab.Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours and aims to evaluate the safety and efficacy of two routes of administration, intratumoural injection and intravenous infusion, either alone or in combination with blinatumomab.

https://www.m a r ketindex.com.au/asx/imu
Shareholder DistributionAs reported in the most recent Annual Report. (use the link if the formatting fails in the post)
Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders613 6,405 3,929 11,903 5,112 27,962
Last Annual report indicated under 30,000 people hold IMU shares. This will change if they cure cancer!